Correspondence 0001140361-23-040517 from Ernexa Therapeutics Inc. (ERNA)
Ernexa Therapeutics Inc.
Date: Aug. 18, 2023 · CIK: 0000748592 · Accession: 0001140361-23-040517
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-273977
Letter
VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Attention: Tim Buchmiller Eterna Therapeutics Inc. (the “Company”) Registration Statement on Form S-3 (the “Registration Statement”) Filed August 14, 2023 File No. 333-273977
Dear Mr. Buchmiller:
The Company hereby requests, pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, acceleration of effectiveness of the Registration Statement so that such Registration Statement will become effective as of 5:00 p.m. on August 22, 2023, or as soon thereafter as practicable.
[Signature page follows]
Very truly yours,
Eterna Therapeutics Inc.
Show Raw Text
CORRESP
1
filename1.htm
Eterna Therapeutics Inc.
1035 Cambridge Street, Suite 18A
Cambridge, MA 02141
August 18, 2023
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, NE
Washington, D.C. 20549
Attention: Tim Buchmiller
RE:
Eterna Therapeutics Inc. (the “Company”)
Registration Statement on Form S-3 (the “Registration Statement”)
Filed August 14, 2023
File No. 333-273977
Dear Mr. Buchmiller:
The Company hereby requests, pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, acceleration of
effectiveness of the Registration Statement so that such Registration Statement will become effective as of 5:00 p.m. on August 22, 2023, or as soon thereafter as practicable.
[Signature page follows]
Very truly yours,
Eterna Therapeutics Inc.
By:
/s/ Matthew Angel
Name: Matthew Angel
Title: Chief Executive Officer and President